ReportWire

Tag: Put

  • Short Interest in SPDR MSCI Emerging Markets StrategicFactors ETF (NYSEARCA:QEMM) Grows By 48.8%

    SPDR MSCI Emerging Markets StrategicFactors ETF (NYSEARCA:QEMM – Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 12,656 shares, an increase of 48.8% from the December 31st total of 8,508 shares. Based on an average daily volume of 4,576 shares, the days-to-cover ratio is presently 2.8 days. Currently, 2.0% of the company’s stock are short sold. Currently, 2.0% of the company’s stock are short sold. Based on an average daily volume of 4,576 shares, the days-to-cover ratio is presently 2.8 days.

    Institutional Investors Weigh In On SPDR MSCI Emerging Markets StrategicFactors ETF

    Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its holdings in SPDR MSCI Emerging Markets StrategicFactors ETF by 5.2% during the second quarter. Bank of America Corp DE now owns 5,377 shares of the company’s stock worth $339,000 after acquiring an additional 268 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of SPDR MSCI Emerging Markets StrategicFactors ETF in the second quarter valued at $28,000. Cabot Wealth Management Inc. raised its holdings in SPDR MSCI Emerging Markets StrategicFactors ETF by 2.5% in the 2nd quarter. Cabot Wealth Management Inc. now owns 28,364 shares of the company’s stock valued at $1,788,000 after acquiring an additional 692 shares during the period. Premier Path Wealth Partners LLC increased its stake in shares of SPDR MSCI Emerging Markets StrategicFactors ETF by 1.8% during the third quarter. Premier Path Wealth Partners LLC now owns 47,115 shares of the company’s stock worth $3,123,000 after purchasing an additional 829 shares during the period. Finally, Portland Financial Advisors Inc bought a new position in SPDR MSCI Emerging Markets StrategicFactors ETF during the 3rd quarter worth $201,000.

    SPDR MSCI Emerging Markets StrategicFactors ETF Stock Down 1.8%

    Shares of QEMM stock opened at $70.55 on Friday. The company has a market capitalization of $43.74 million, a price-to-earnings ratio of 14.30 and a beta of 0.57. SPDR MSCI Emerging Markets StrategicFactors ETF has a 12-month low of $51.72 and a 12-month high of $72.82. The firm has a fifty day moving average of $67.15 and a 200-day moving average of $66.33.

    SPDR MSCI Emerging Markets StrategicFactors ETF Company Profile

    (Get Free Report)

    The SPDR MSCI Emerging Markets StrategicFactors ETF (QEMM) is an exchange-traded fund that is based on the MSCI EM Factor Mix A-Series (USD) index. The fund tracks an index of emerging-market securities equally-weighted between 3 sub-indexes that focus on value, minimum volatility and quality. QEMM was launched on Jun 4, 2014 and is managed by State Street.

    Recommended Stories



    Receive News & Ratings for SPDR MSCI Emerging Markets StrategicFactors ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SPDR MSCI Emerging Markets StrategicFactors ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Short Interest in NagaCorp Ltd. (OTCMKTS:NGCRF) Declines By 50.6%

    NagaCorp Ltd. (OTCMKTS:NGCRF – Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 11,700 shares, a decrease of 50.6% from the August 15th total of 23,700 shares. Based on an average daily volume of 1,000 shares, the short-interest ratio is currently 11.7 days. Based on an average daily volume of 1,000 shares, the short-interest ratio is currently 11.7 days.

    NagaCorp Price Performance

    Shares of NGCRF opened at $0.78 on Friday. NagaCorp has a 52 week low of $0.33 and a 52 week high of $0.78. The company has a 50-day simple moving average of $0.59 and a 200-day simple moving average of $0.49.

    NagaCorp Dividend Announcement

    The firm also recently announced a dividend, which will be paid on Tuesday, September 30th. Investors of record on Wednesday, September 10th will be paid a $0.0101 dividend. The ex-dividend date of this dividend is Tuesday, September 9th. This represents a yield of 142.0%. NagaCorp’s payout ratio is presently 37.44%.

    NagaCorp Company Profile

    (Get Free Report)

    NagaCorp Ltd., an investment holding company, manages and operates a hotel and casino complex in the Kingdom of Cambodia. The company operates in two segments, Casino Operations; and Hotel and Entertainment Operations. It owns, manages, and operates NagaWorld, an integrated hotel and entertainment complex that consists of rooms and suites, gaming tables, and electronic gaming machines, as well as public and premium gaming halls, all-suite luxury spa, shopping gallery, food and beverage outlets and clubs, entertainment services, and meeting spaces, as well as hotel convention spaces.

    See Also



    Receive News & Ratings for NagaCorp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NagaCorp and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Jiangsu Expressway Company Limited (OTCMKTS:JEXYY) Short Interest Update

    Jiangsu Expressway Company Limited (OTCMKTS:JEXYY) Short Interest Update

    Jiangsu Expressway Company Limited (OTCMKTS:JEXYY – Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,000 shares, a decrease of 9.1% from the August 15th total of 1,100 shares. Based on an average daily volume of 1,000 shares, the short-interest ratio is presently 1.0 days.

    Jiangsu Expressway Price Performance

    OTCMKTS:JEXYY opened at $20.45 on Wednesday. Jiangsu Expressway has a 12 month low of $17.21 and a 12 month high of $22.40. The business’s fifty day moving average price is $19.61 and its 200 day moving average price is $20.31.

    About Jiangsu Expressway

    (Get Free Report)

    Jiangsu Expressway Company Limited engages in investment, construction, operation, and management of toll roads and bridges in the People’s Republic of China. The company operates the Jiangsu section of Shanghai-Nanjing Expressway, Ningchang Expressway, Zhenli Expressway, Guangjing Expressway, Xicheng Expressway, Xiyi Expressway, Zhendan Expressway, Yanjiang Expressway, Jiangyin Bridge, Sujiahang Expressway, Changyi Expressway, Yichang Expressway, and Wufengshan Bridge.

    Read More

    Receive News & Ratings for Jiangsu Expressway Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jiangsu Expressway and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • unsafe tame acceptable

    unsafe tame acceptable

    Now empty dog bed. Had to put down my 14 y.o dog I raised from puppy ’cause of tumor. Decided that it’s better to let go instead of trying surgery that most likely would’ve been fatal anyway ’cause of old age. Now my other dog is searching for his cousin frantically without avail.

    Source link

  • ‘Vanderpump Rules’ Gets Put on Pause. Plus, ‘The Valley,’ ‘Summer House,’ and ‘Summer House: Martha’s Vineyard.’

    ‘Vanderpump Rules’ Gets Put on Pause. Plus, ‘The Valley,’ ‘Summer House,’ and ‘Summer House: Martha’s Vineyard.’

    Bravo

    Rachel and Callie get into the Bravo news of the week, ‘Vanderpump Rules’ updates, and more

    Rachel Lindsay and Callie Curry team up on this week’s Morally Corrupt to first bring you the Bravo news of the week (4:26). They then launch into a larger discussion about Vanderpump Rules Season 11, Episode 14 (10:49). Later, Rachel and Callie chat briefly about The Valley (37:34), and eventually move on to both iterations of Summer House (48:56).

    Host: Rachel Lindsay
    Guest: Callie Curry
    Producer: Devon Baroldi
    Theme Song: Devon Renaldo

    Subscribe: Spotify

    Rachel Lindsay

    Source link

  • Sad – lost a good one

    Sad – lost a good one


    My dog was put to sleep last night. She was my first dog and I had her for almost 10 years. She was the moodiest bitch on the planet but was always super sweet to me. I’ll miss hearing her close the laundry room door to hide from my kids and catch a break.
    This is a toast to a real one.
    Fry up some bacon just for your puppies once in a while. They deserve it.



    Source link

  • Dex-Starr is the goodest of kitties

    Dex-Starr is the goodest of kitties

    context:
    cat is put in a bad cause its trying its best to protect his human, some ******* throw him into a river, the anger he feels is so strong that it makes him worthy of a red ring,
    his human gets killed so he hunts down the ******* that did it and kills them all

    Source link

  • What if Super Mario Bros. Wonder’s talking flowers were in Alan Wake 2?

    What if Super Mario Bros. Wonder’s talking flowers were in Alan Wake 2?

    Alan Wake 2 is bleak stuff. Sure, your flashlight makes the darkness a little less scary, and the full-motion video commercials are a lighthearted wink to players who seek them out. But for some, the game could benefit from a constant positive presence to raise the mood while you traverse the Overlap and beyond.

    Of course, this thought comes after playing Super Mario Bros. Wonder, where each level features a goofy talking flower character who remarks on the player’s actions, or on what’s happening in the game world. After going back and forth between the two games, it’s hard not to imagine what the talking flower would be like in Alan Wake 2.

    Image composition: Cameron Faulkner/Polygon | Source images: Remedy Entertainment/Epic Games Publishing, Nintendo EPD/Nintendo

    Beyond blurting out quips to take your mind off the dread of walking through forests at night with scarily few bullets, or when running from the Dark Presence, the talking flower could be a useful tool for marking objectives, or helping you figure out combinations to safes.

    Inevitably, I think the game would take a dark turn with this, turning the talking flower into a deceptive plot device. Eventually you wouldn’t know if you could trust what the talking flower is telling you, adding to Alan Wake 2’s deft skill of extending its dark fiction over the game’s reality. Are the Taken a threat, or are you the threat? Maybe, just maybe, it’s the talking flower.

    It’s putting thoughts into my mind, ones that I’d rather not be having.

    The chaos is reminding me of how simple things were, back when Alice and I first arrived in Bright Falls. Now, I’m stuck in the Dark Place.

    T̶̘͉̯̀̾̑̈́̈́͑̏̚̕͝h̸̝͔̭̹͎̲̦̖͉͓̊͊̒̓̎͒̑̚͜e̶̢̛̦̠̤̳͍̭̠̠͊̄̑̓̌̂̍̐̍͝ ̵͈͚̞̑͛̀̈́̅ţ̶̧̭̜̙̥̀̐̔͜ă̶̲̬̞͔̠͚̪̣̤̎̀̂̈́̕ḽ̸̬̬͎͙̥̘̈͐͗͋͋͋̍̌̀͛̕̕͠k̸̖͎̙̭̖̝̎̽̃̀͊̃̏̑̾̃͒ḭ̶̧̠͙͕̺͎͊̄̈́̾̇̈̐͋̏͘͝ń̸̢̮̩̰͙͌̆͛g̴̞͖͖͉̭͚̞͋́̒̈̃̄̾͗͂̈̎͘̚ ̵̢͎̺͎̙̭͕̹̞̑̆̈́̿f̴̨̨̧̱͖̫̱̥̖̩̝̯͇̪̀͋̒͐͗̓̎͗̂͐͜͠ĺ̸̡̦̼̖̦͔̗̳̭̫̼̳̘̱̝̎̂͛́̀̓̇̈̎͝o̷̡͓̭̞̲̯̞̘͊̈́̉͋̾̿̓̔̈̅͌͜͝ͅw̴̘͖̉̈́̽͗̏̈́̄̈́̓̈́̓̕͠ȩ̸̡̞̱̟̺̹̲͍͖̹̹̀̈́͒̆̀̊̾̉̑̽̑̕͠ͅŗ̷͉̝̘͚͉̱̫̰̈́ ̸̺̥̤̞̭͙̗͚͍̗̺͈͔̣̃͜͠ḩ̴̡̧̰͕͈̩̱̲̯͚̥͚̦́̇͜a̶̜̰̝̼̬̦̼͓͊̉̈́ṡ̸̡̟̩͎̗̘̭͕͕͍͍͖̠͜ ̵̗̬͉̜̩̂t̵̹͓͍̯̤̭͍̻̹̟͚̎͐͛͠ą̵̟̠̬̮̌̊̍̿̒̂̊͌͋̐̚͝k̶̨̛̝̻̫͕͇̙̼͎̞͕͓̥͒͂̔̽̀̑͒̏̚͜͝ȩ̴̝͓̬̝̘̘̙̤̰̫̞̤̈̎̏̐̒̋̏͋͊͝n̸̢̛̠̖͚̠͎͆̂͛̑́͠ͅ ̵̢̘̹͓͖̘̽͛̀͋̐̚m̵̛͚̊̃͂̃̆̋̓̂͛͆̋̎̃͌y̴̙͖͔̳͍͍̟̫̩͎̙̟̔͛̔̏̓̇̀̈́͆̀ͅͅͅ ̶̠͓̝͉̬̤̟̼̞͉͚͋̇̂͗́ͅp̴̨̞̲̹̩̙̫̖͉̩̠̗̜̀͜l̷̲͚̱͉͓̥̪͑̓̔͛̿̐͋͑͂̈́͘͜ã̸̢͚͓͚͔͊̓̒̈̎̆̾̎̚ç̶̟̤̟̯̘̖̝̫͎̣̹̚e̸̜͓̯͐̑̾̈́̂̉̓̆̐͝ ̶̙̖̲̮̏͌͜ͅí̸̯̇̇̇̆̄̔͋͊̾̋͠n̵̨̠̙̟͎̏́̄̓̔͗̀̚͝͝ ̶̜̞̥̭̰̼̖̞̖̭̈̂͒͒̓͑͛̾̐̽̿̕̕͝͝ŗ̴̮̜̼̔͗͋̉ͅę̷͍̥͖̞̻̗͓͓̥̎̅͑̅̾̓̾̃̿̄̕͠ä̸̛̻̎̅̔̈̈́̅̀̎̂̈́̚͝͝ļ̷͕̫̫̜̄̉́̎̐͝į̷͎͇̖̖͚̍̓̀̉̂́̏͂͑̂͌̕ͅt̷̡͉͎͓̻͙̩͍̙͈͋̏̈̏̎̉̀̕y̵͙͉̩̘̐̈́̃̄́̉̓̍̀̂̅̔͝.̵̢̡̢̭̻̝̭͎͔͖̻͔̓̀͜͜͠ͅ

    Cameron Faulkner

    Source link

  • Goodbye my hound.

    Goodbye my hound.

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    Goodbye my hound.. This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times

    This morning I had to have my dog Skelum put down after he suffered a stroke. He had been with me 15 years, helped me through many hard times, saw me get married and has helped me play with and protect my four children.
    Goodbye my faithful hound, my best friend. I’ll always love you.
    I’ll see you in the next place.

    Source link

  • Stocks are trapped in a trading range. Something’s got to give.

    Stocks are trapped in a trading range. Something’s got to give.

    The U.S. stock market, as measured by the S&P 500 Index SPX, is trapped in a trading range, and volatility seems to be damping down considerably. The significant edges of the trading range are support at 4330 and resistance at 4540. Both of those levels were touched in the latter half of August. A breakout from this range should give the market some strong directional momentum. 

    Since Labor Day, prices have hunkered down into an even narrower range. Typically, the latter half of September through the early part of October…

    Source link

  • Algoma Steel Group Sees Unusually High Options Volume (NASDAQ:ASTL)

    Algoma Steel Group Sees Unusually High Options Volume (NASDAQ:ASTL)

    Algoma Steel Group Inc. (NASDAQ:ASTL – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock investors bought 11,996 call options on the stock. This represents an increase of 855% compared to the average daily volume of 1,256 call options.

    Hedge Funds Weigh In On Algoma Steel Group

    A number of hedge funds have recently added to or reduced their stakes in ASTL. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in shares of Algoma Steel Group by 3.9% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 41,422 shares of the company’s stock worth $262,000 after buying an additional 1,571 shares during the last quarter. ARS Investment Partners LLC lifted its stake in shares of Algoma Steel Group by 4.1% in the first quarter. ARS Investment Partners LLC now owns 51,000 shares of the company’s stock worth $412,000 after buying an additional 2,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Algoma Steel Group by 26.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,093 shares of the company’s stock worth $83,000 after purchasing an additional 2,735 shares during the period. LPL Financial LLC raised its stake in Algoma Steel Group by 14.3% during the fourth quarter. LPL Financial LLC now owns 25,385 shares of the company’s stock worth $161,000 after purchasing an additional 3,170 shares during the period. Finally, Barclays PLC increased its position in shares of Algoma Steel Group by 35.4% during the fourth quarter. Barclays PLC now owns 12,237 shares of the company’s stock valued at $78,000 after acquiring an additional 3,200 shares during the last quarter. 62.44% of the stock is currently owned by institutional investors.

    Algoma Steel Group Price Performance

    ASTL stock opened at $7.47 on Thursday. The firm has a 50 day moving average price of $7.30 and a 200-day moving average price of $7.56. Algoma Steel Group has a 52-week low of $5.64 and a 52-week high of $9.94. The firm has a market capitalization of $773.89 million, a price-to-earnings ratio of 24.90 and a beta of 1.46. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.87 and a current ratio of 3.49.

    Algoma Steel Group (NASDAQ:ASTL – Get Free Report) last posted its earnings results on Thursday, August 10th. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.12). Algoma Steel Group had a return on equity of 8.67% and a net margin of 4.90%. The company had revenue of $615.87 million during the quarter, compared to the consensus estimate of $596.30 million. During the same period last year, the firm posted $1.17 EPS. Equities research analysts forecast that Algoma Steel Group will post 1.73 EPS for the current fiscal year.

    Algoma Steel Group Announces Dividend

    The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, August 25th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Thursday, August 24th. This represents a $0.20 dividend on an annualized basis and a yield of 2.68%. Algoma Steel Group’s dividend payout ratio is currently 66.67%.

    Algoma Steel Group Company Profile

    (Get Free Report)

    Algoma Steel Group Inc produces and sells steel products primarily in North America. The company provides flat/sheet steel products, including temper rolling, cold rolled, hot-rolled pickled and oiled products, floor plate, and cut-to-length products for the automotive industry, hollow structural product manufacturers, and the light manufacturing and transportation industries; and plate steel products that consist of rolled, hot-rolled, and heat-treated for use in the construction or manufacture of railcars, buildings, bridges, off-highway equipment, storage tanks, ships, and military applications.

    Recommended Stories

    Receive News & Ratings for Algoma Steel Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Algoma Steel Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)

    Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw some unusual options trading on Thursday. Investors acquired 3,690 call options on the stock. This represents an increase of 52% compared to the typical volume of 2,435 call options.

    Iovance Biotherapeutics Price Performance

    Shares of IOVA stock opened at $7.76 on Friday. The company has a fifty day moving average price of $7.87 and a two-hundred day moving average price of $7.03. The stock has a market cap of $1.74 billion, a P/E ratio of -3.23 and a beta of 0.11. Iovance Biotherapeutics has a one year low of $5.28 and a one year high of $13.44.

    Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.34. During the same quarter in the prior year, the business earned ($0.58) earnings per share. As a group, equities research analysts anticipate that Iovance Biotherapeutics will post -2.4 EPS for the current fiscal year.

    Institutional Investors Weigh In On Iovance Biotherapeutics

    A number of institutional investors have recently modified their holdings of IOVA. Assetmark Inc. increased its stake in shares of Iovance Biotherapeutics by 299.5% in the first quarter. Assetmark Inc. now owns 4,223 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 3,166 shares in the last quarter. US Bancorp DE raised its stake in shares of Iovance Biotherapeutics by 72.7% during the first quarter. US Bancorp DE now owns 5,591 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,354 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Iovance Biotherapeutics by 54.5% in the third quarter. Royal Bank of Canada now owns 5,066 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,787 shares during the period. Systematic Financial Management LP bought a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $48,000. Finally, Lazard Asset Management LLC boosted its stake in Iovance Biotherapeutics by 38.5% in the 1st quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 934 shares in the last quarter. 89.80% of the stock is owned by institutional investors.

    Wall Street Analysts Forecast Growth

    A number of brokerages have issued reports on IOVA. Wells Fargo & Company raised shares of Iovance Biotherapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $17.00 in a report on Tuesday, May 30th. Robert W. Baird boosted their price target on shares of Iovance Biotherapeutics from $20.00 to $23.00 in a report on Tuesday, May 23rd. Stifel Nicolaus boosted their target price on shares of Iovance Biotherapeutics from $21.00 to $24.00 in a research report on Tuesday, May 30th. Finally, StockNews.com upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Sunday, July 9th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.09.

    Iovance Biotherapeutics Company Profile

    (Get Free Report)

    Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer.

    Recommended Stories

    Receive News & Ratings for Iovance Biotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Iovance Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Affimed (NASDAQ:AFMD) Sees Large Decline in Short Interest

    Affimed (NASDAQ:AFMD) Sees Large Decline in Short Interest

    Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 3,140,000 shares, a decrease of 7.9% from the January 15th total of 3,410,000 shares. Based on an average daily trading volume, of 2,040,000 shares, the days-to-cover ratio is currently 1.5 days.

    Analyst Upgrades and Downgrades

    AFMD has been the subject of several analyst reports. SVB Leerink decreased their target price on Affimed from $10.00 to $6.00 and set an “outperform” rating for the company in a research report on Monday, December 12th. StockNews.com upgraded Affimed from a “sell” rating to a “hold” rating in a report on Monday, November 21st. Truist Financial lowered their price target on Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Piper Sandler decreased their price objective on Affimed from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, December 12th. Finally, HC Wainwright started coverage on shares of Affimed in a report on Monday, December 12th. They set a “buy” rating and a $6.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.71.

    Hedge Funds Weigh In On Affimed

    Several hedge funds have recently modified their holdings of the stock. Advisor Group Holdings Inc. boosted its position in Affimed by 258.3% during the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 6,464 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Affimed by 23.9% in the 1st quarter. JPMorgan Chase & Co. now owns 68,895 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 13,300 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Affimed by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock valued at $1,323,000 after buying an additional 5,513 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Affimed during the 1st quarter worth about $726,000. Finally, Vanguard Group Inc. raised its holdings in shares of Affimed by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock valued at $6,060,000 after purchasing an additional 5,499 shares during the period. Institutional investors own 61.73% of the company’s stock.

    Affimed Price Performance

    Shares of AFMD opened at $1.00 on Friday. The company has a quick ratio of 5.63, a current ratio of 5.65 and a debt-to-equity ratio of 0.07. Affimed has a twelve month low of $0.99 and a twelve month high of $5.10. The stock has a market capitalization of $123.42 million, a P/E ratio of -1.59 and a beta of 2.35. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.90.

    Affimed (NASDAQ:AFMD – Get Rating) last released its earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.08. Affimed had a negative net margin of 189.04% and a negative return on equity of 48.46%. The business had revenue of $15.01 million during the quarter, compared to the consensus estimate of $7.66 million. As a group, equities research analysts forecast that Affimed will post -0.61 EPS for the current fiscal year.

    About Affimed

    (Get Rating)

    Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.

    See Also

    Receive News & Ratings for Affimed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Affimed and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Interpublic Group of Companies Target of Unusually Large Options Trading (NYSE:IPG)

    Interpublic Group of Companies Target of Unusually Large Options Trading (NYSE:IPG)

    The Interpublic Group of Companies, Inc. (NYSE:IPG – Get Rating) was the recipient of unusually large options trading activity on Thursday. Investors bought 12,009 put options on the company. This represents an increase of approximately 3,254% compared to the typical volume of 358 put options.

    Interpublic Group of Companies Stock Performance

    NYSE:IPG opened at $35.70 on Friday. Interpublic Group of Companies has a 1 year low of $25.14 and a 1 year high of $39.98. The firm has a 50 day moving average of $32.70 and a 200-day moving average of $29.75. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $13.87 billion, a P/E ratio of 14.17, a price-to-earnings-growth ratio of 8.72 and a beta of 1.08.

    Interpublic Group of Companies (NYSE:IPG – Get Rating) last posted its quarterly earnings data on Friday, October 21st. The business services provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Interpublic Group of Companies had a net margin of 9.18% and a return on equity of 28.78%. The firm had revenue of $2.30 billion during the quarter, compared to analysts’ expectations of $2.29 billion. As a group, sell-side analysts anticipate that Interpublic Group of Companies will post 2.74 EPS for the current fiscal year.

    Interpublic Group of Companies Announces Dividend

    The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 15th. Investors of record on Thursday, December 1st were given a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend was Wednesday, November 30th. Interpublic Group of Companies’s dividend payout ratio (DPR) is presently 46.03%.

    Analysts Set New Price Targets

    A number of research analysts have commented on IPG shares. StockNews.com started coverage on shares of Interpublic Group of Companies in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Barclays cut their price target on shares of Interpublic Group of Companies from €35.00 ($37.23) to €33.00 ($35.11) and set an “equal weight” rating for the company in a research note on Friday, September 16th. Morgan Stanley raised their price target on shares of Interpublic Group of Companies from $33.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Monday, December 19th. Finally, Bank of America upgraded shares of Interpublic Group of Companies from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $22.00 to $36.00 in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Interpublic Group of Companies has a consensus rating of “Moderate Buy” and an average target price of $36.25.

    Institutional Inflows and Outflows

    Institutional investors have recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. bought a new position in Interpublic Group of Companies in the 2nd quarter worth approximately $26,000. Venture Visionary Partners LLC acquired a new stake in Interpublic Group of Companies during the 2nd quarter worth $26,000. Concord Wealth Partners grew its holdings in Interpublic Group of Companies by 251.5% during the 2nd quarter. Concord Wealth Partners now owns 942 shares of the business services provider’s stock worth $26,000 after acquiring an additional 674 shares during the period. Ten Capital Wealth Advisors LLC acquired a new stake in Interpublic Group of Companies during the 3rd quarter worth $31,000. Finally, Private Trust Co. NA acquired a new stake in Interpublic Group of Companies during the 2nd quarter worth $36,000. Institutional investors own 96.75% of the company’s stock.

    About Interpublic Group of Companies

    (Get Rating)

    The Interpublic Group of Companies, Inc provides advertising and marketing services worldwide. It operates in two segments, Integrated Agency Networks (IAN) and IPG DXTRA. The company offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines, as well as data science services.

    Recommended Stories

    Receive News & Ratings for Interpublic Group of Companies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Interpublic Group of Companies and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link